NCT02803203 - Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 29, 2016

Primary Completion Date

March 1, 2022

Study Completion Date

March 1, 2022

Conditions

Non-small Cell Lung CancerEGFR-mutant Lung Cancers

Interventions

DRUG

osimertinib

DRUG

Bevacizumab

Trial Locations (7)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Nassau, Uniondale

Memorial Sloan Kettering commack, Commack

Memoral Sloan Kettering Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering Bergen, Montvale